These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35948003)

  • 41. Biomarker-driven management strategies for peripheral T cell lymphoma.
    Mulvey E; Ruan J
    J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
    Veyri M; Spano JP; Le Bras F; Marcelin AG; Todesco E
    Br J Haematol; 2023 Jun; 201(6):1033-1046. PubMed ID: 37170397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.
    Irimia R; Barbu S; Popa C; Badelita S
    Hematol Rep; 2023 Mar; 15(1):220-224. PubMed ID: 36975736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
    Marques-Piubelli ML; Kim DH; Medeiros LJ; Lu W; Khan K; Gomez-Bolanos LI; Rodriguez S; Parra ER; Ok CY; Aradhya A; Solis LM; Nieto YL; Steiner R; Ahmed S; Vega F
    Histopathology; 2023 Jul; 83(1):143-148. PubMed ID: 36994939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
    Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
    Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas.
    Burton JS; Foley NC; Mehta-Shah N
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):65-76. PubMed ID: 37973458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study.
    Wang Y; Zhang F; Gao N; Bu P; Cui W; Xi Y
    Medicine (Baltimore); 2023 Nov; 102(46):e35531. PubMed ID: 37986346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series.
    Arroyo-Andrés J; Agud-Dios M; Rubio-Muniz CA; Postigo C; Cortijo-Cascajares S; Ortiz-Romero PL
    Int J Dermatol; 2024 Feb; 63(2):e57-e59. PubMed ID: 38093412
    [No Abstract]   [Full Text] [Related]  

  • 49. Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.
    Wang Y; Wang Z; Wei C; Zhao D; Zhang Y; Wang W; Zhang W; Zhou D
    Ann Hematol; 2023 Oct; 102(10):2973-2975. PubMed ID: 37522969
    [No Abstract]   [Full Text] [Related]  

  • 50. Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
    Ong SY; Zain JM
    Am J Hematol; 2024 Mar; 99(3):439-456. PubMed ID: 38304959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin.
    Meconi F; Provenzano I; Nasso D; Mariotti B; Pupo L; Secchi R; Cerretti R; Lucia A; Arcese W; Cantonetti M
    Clin Case Rep; 2020 Aug; 8(8):1353-1356. PubMed ID: 32884752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insights into uveitis from Brentuximab vedotin in refractory Hodgkin's lymphoma: a case report and brief review.
    Liu M; Ren K; Ai P; Zou L
    Front Oncol; 2024; 14():1419145. PubMed ID: 39161379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
    Gru AA; Lim MS; Dogan A; Horwitz SM; Delabie J; Fu K; Peker D; Reddy VVB; Xu ML; Vij K; Slack GW; Miranda RN; Jagadeesh D; Lisano JM; Hsi ED; Torlakovic E
    Arch Pathol Lab Med; 2023 Jan; 147(1):79-86. PubMed ID: 35472771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Oymanns M; Daum-Marzian M; Bellm A; Elsayad K; Eich HT; Assaf C
    Br J Dermatol; 2023 Jan; 188(1):145-146. PubMed ID: 36689504
    [No Abstract]   [Full Text] [Related]  

  • 55. Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
    Asrani R; Cengiz TB; Petersen BE; Anagnostou T; Brody JD
    Front Oncol; 2023; 13():1254256. PubMed ID: 38313213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT.
    Giza A; Miklusiak K; Hałubiec P; Jaworek A; Zimowska-Curyło D; Dyduch G; Sacha T
    Case Rep Dermatol; 2023; 15(1):110-116. PubMed ID: 37497303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging strategies in peripheral T-cell lymphoma.
    Mehta-Shah N
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):41-46. PubMed ID: 31808829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.
    Li Z; Guo W; Bai O
    Front Oncol; 2023; 13():1301437. PubMed ID: 38188299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry.
    Li S; Zheng S; Huang X; Zhang W; Liu F; Cao Q
    Fetal Pediatr Pathol; 2024; 43(2):111-122. PubMed ID: 38213180
    [No Abstract]   [Full Text] [Related]  

  • 60. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.
    Pincez T; Bruneau J; Berteloot L; Piekarski E; Thomas C; Marçais A; Trinquand A; Castelle M; Garcelon N; Plantaz D; Cheminant M; Moshous D; Molina TJ; Hermine O; Macintyre E; Fischer A; Blanche S; Suarez F; Neven B
    Haematologica; 2020 Sep; 105(9):e461-464. PubMed ID: 33054064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.